CST3 and cancer: Third, we were not able to identify cancer stage and measures of functional status from the electronic health record, each of which may be important non-GFR factors in cystatin C and SCr.58,59 Fourth, clinician knowledge of the eGFRcys could have altered medication dosing; however, such practice would have biased the results toward the null.